Winter 2006

IN THIS ISSUE:

urnham expansion B in Florida

T EAM BURNHAM— for Medical Research

F ire & Ice: Burnham’s best gala yet!

The Burnham Report Volume 3, Number 3 | 2006

NCI Cancer Center

at Burnham

In this issue...

Volume 3 | Number 3 | 2006

PAGE

CONTENT

President’s Message

1

RESEARCH MATTERS

2

NCI Cancer Center at 25

4

Profile of Dr. Kristiina Vuori, Cancer Center Director

THE BURNHAM REPORT

PHILANTHROPY MATTERS

John C. Ph.D. John C. Reed, M.D., Ph.D. President and CEO

6

Team Burnham for Medical Research

7

Remembering Eric Dudl

8

Fire & Ice Gala

Karin Eastham Karin Eastham Executive Vice President and COO Blair Blum Blair Blum Senior Vice President, External Relations

10

STARS and the Burnham Institute for

Edgar Gillenwaters Edgar Gillenwaters Vice President, External Relations

Medical Research

Chris Lee Chris Lee Director, External Relations

11

Profile of a Donor: Gwen Laidlaw

Nancy J. Beddingfield Report Editor, The TheBurnham Burnham Report

12

Our Wish List

13

Burnham in the Community

14

Calendar of Events

www.burnham.org MALINDA DANZIGER Coordinator, Marketing and Public Relations

The Burnham Report is published www.burnham.org

four times each year by the Burnham Institute for Medical Research.

The Burnham Report is published by We welcome your input.

Please the Burnham Institute for Medical send comments or requests Research. We welcome yourto input. info@burnham.org.

Please send comments or requests to info@burnham.org.

The Burnham Report is available

as virtual magazine at To a subscribe to future issues of the www.burnham.org.

Burnham Report Click Here.

Cover Legend As we mark our 25th in year in partnership with the National Cancer Institute as an NCI-designated Cancer Center, we salute our scientists who, each day, contribute new information to the world’s knowledge about cancer that will yield new ways to detect, treat, cure, and ultimately, prevent suffering and death from this disease.

10901 North Torrey Pines Road La Jolla, CA 92037

www.burnham.org

President’s Message We recently announced plans to establish a 300-person operation in Orlando, Florida.

Our Florida operations will extend our existing capabilities in chemistry, pharmacology, and functional genomics, technological themes that will complement and fortify

Governor Jeb Bush and Dr. John Reed announce Burnham’s planned expansion in Orlando, Florida at a press conference in Tallahassee. Photo courtesy the Governor’s office.

the Institute’s current commitments to cancer, degenerative diseases, infectious and inflammatory disease, while allowing developing discovery research in areas such as diabetes and obesity.

Burnham’s expansion into Florida has been made possible through a unique partnership with the State of Florida, Orange County, the City of Orlando, the University of Central Florida, the University of Florida, the Tavistock Group, Florida’s Blood Centers, and Florida’s philanthropic community. We are grateful to the people of Florida for their generous support of our medical research efforts and to Governor Jeb Bush and the Florida State Legislature for providing the financial means for our expansion into Florida. As we build our Florida operation from the ground up— literally—we will keep you apprised of our progress in future issues of The Burnham Report.

Whether we’re helping young medical researchers launch their careers, training graduate students and postdoctoral fellows, building scientific teams to tackle medical problems, or testing a new idea about disease with a pilot study, all of Burnham’s progress is seeded in the generosity of our donor community. This year, our fifth annual gala netted $850,000. Our success was rooted in the enthusiastic support of the 450 guests who joined us for the evening. We have captured a few of the many highlights on pages 8 and 9.

Generosity comes in many forms, and I am enormously proud of the many people who have joined me in training for the Phoenix Rock ‘n’ Roll Marathon on January 14, 2007 as Team Burnham For Medical Research.

According to Elite Racing, race organizer of this and most of the nation’s major running events, Team Burnham is the largest first-year charitable team ever assembled for such an endeavor. I am particularly gratified that more than 1/2 of my teammates are Burnham employees, each of whom has pledged to raise $3,000 in support of the Institute’s medical research. As we head into our final month of training, I challenge you to join us! The article on page 6 outlines many ways in which you can support Team Burnham.

Our cover story celebrates the Burnham’s 25-year partnership with the National Cancer Institute (NCI) as an NCI-designated Cancer Center. In this article you will learn about some of Burnham’s unique contributions to the next generation of cancer treatments through the perspective of our newly appointed Cancer Center Director Dr. Kristiina Vuori.

While we were collecting our thoughts for this cover story, the unthinkable happened: we lost one of our own researchers to cancer. Dr. Eric Dudl was a postdoctoral fellow training in my laboratory when he was stricken with cancer. Eric set an inspiring example, spending every possible moment focused on his research, right up until his untimely death at age 33. We dedicate this issue of The Burnham Report to Eric Dudl and his family. I invite you to learn more about his legacy on page 7.

John C. Reed, M.D., Ph.D. President and CEO www.burnham.org

1

Burnham’s NCI

Cancer Center at

25

Research at Burnham’s Cancer Center is yielding tangible medical benefits, including diagnostic procedures and novel therapeutic agents.

For 25 years, members of the NCI-designated Cancer Center at Burnham have been deeply involved in understanding the mechanisms underlying the transformation of normal cells into “rogue cells,” which ignore the rules governing cellular lifespan, growth, tissue localization and give rise to cancer.

We take pride in the fact that ongoing research at Burnham’s Cancer Center is yielding tangible medical benefits, including diagnostic procedures and novel therapeutic agents. Currently, three approved drugs and at least five experimental therapies for cancer are in final Phase III clinical trials and can be traced to the work of Burnham scientists.

2

www.burnham.org

Drs. Marcia Dawson and Xiaokun Zhang collaborated to synthesize and characterize a Vitamin A derivative which has been developed into the drug Targretin™. Targretin™, the world’s first cancer treatment based on an enhanced version

Dr. Erkki Ruoslahti, Distinguished Professor

cancer. Dr. Reed and Burnham collaborator Dr. Maurizio Pellecchia continued work on this cancer-related protein, called Bcl-2, producing several lead compounds in various phases of evaluation and testing for further

Dr. Erkki Ruoslahti dedicates his cancer research to understanding and controlling the spread of cancer. of Vitamin A, has been approved as a treatment for cutaneous T-cell lymphoma.

Dr. John Reed invented the world’s first DNA-based drug for cancer to successfully complete Phase III clinical trials. That drug, Genasense™, works by silencing a gene that makes a cell survival protein, Bcl-2. Genasense™ is in final testing for leukemia, melanoma and prostate

development. Dr. Reed’s leadership on this front has been recognized by the NCI with special funding to Burnham as a Center of Excellence for Cancer Drug Discovery, one of only nine in the nation.

Dr. Erkki Ruoslahti dedicates his cancer research to understanding and controlling the spread of cancer. Dr. Ruoslahti’s research

Since 1981, the Burnham Institute for Medical Research has earned recognition from the National Cancer Institute as an NCI - designated cancer center.

This prestigious accreditation provides the Burnham’s Cancer Center with support for pilot projects to test new approaches in cancer research and special funding that allows us to establish cutting-edge technologies that expedite our cancer discoveries and bring them closer to the clinic.

revealed the fundamental mechanisms of cell adhesion

Ruoslahti’s laboratory have been used to target delivery of

Dr. Ruoslahti is developing targeting molecules that will provide the platform for integrating nanotechnologies into the design of new ways to detect, monitor, and treat cancer. and cell migration, work for which he has been awarded many distinguished prizes. The fruits of his research include drugs now in use to prevent platelet adhesions to blood vessels, thus preventing the blood clots that cause heart attack and stroke. Among other accomplishments, Dr. Ruoslahti deciphered the body’s postal zip code system for molecular targeting, discovering that each organ or tissue in the body has a unique zip code posted in its blood and lymphatic vessels.

Molecules discovered in Dr.

toxic cancer drugs selectively into tumors (in mice). Dr. Ruoslahti contributes a key component to a “Center of Cancer Nanotechnology Excellence” at University of California, San Diego founded last year as part of a special initiative funded by the National Cancer Institute.

Targeting molecules developed in his laboratory are providing the delivery platform to use nanotechnologies in the design of new ways to detect, monitor and treat cancer.

Click here to learn more about Burnham’s NCI Cancer Center.

Dr. John Reed, President and CEO

www.burnham.org

3

The Burnham’s Cancer Center The Burnham is pleased to announce the appointment of Dr. Kristiina Vuori as the Director of the Institute’s National Cancer Institute (NCI) - designated Cancer Center. Dr. Vuori is not only the nation’s youngest director of an NCI cancer research center, but is one of only four women

Dr. Kristiina Vuori, Burnham’s NCIdesignated Cancer Center Director

directors among 61 cancer centers. She is also the only woman in the nation directing an NCI Cancer Center with a sole focus on basic cancer research.

Dr. Vuori earned her M.D. and Ph.D. degrees in Finland and trained in gynecologic oncology. As a graduate student, Dr. Vuori discovered the gene for an enzyme called prolyl hydroxylase that regulates collagen synthesis and responsiveness of cells to oxygen, and she developed methods to inhibit this enzyme. Drugs inhibiting prolyl hydroxylase are currently in late-stage clinical trials for treatment of fibrotic disease, anemia, ischemia and cancer.

Dr. Vuori joined Burnham as a postdoctoral fellow with Dr. Erkki Ruoslahti, who was then president and CEO of the Institute. She was recruited to Burnham’s faculty in 1995 and in 1997, she was awarded the prestigious Pew Scholarship in the Biomedical Sciences.

In addition to directing the Cancer Center, Dr. Vuori serves as deputy director of the San Diego Center for Chemical Genomics at Burnham, established by the National Institutes of Health as one of 10 collaborating centers, known collectively as the “Molecular Libraries Screening Centers Network.” This national network represents the world’s largest independent drug discovery effort.

Dr. Vuori’s research is focused on the study of metastasis, the spread of disease from one part of the body to another, the most life-threatening aspect of cancer. Recently, her laboratory published a seminal discovery that defines the origin of cell movement, at its most basic level, inside cells. This knowledge could be key to devising new ways to control the spread of cancer.

Click here to learn more about this discovery.

4

www.burnham.org

Cancer Research

Q &A

We asked Dr. Vuori a few questions about her vision for cancer research at the Burnham and elsewhere.

Q: The Burnham’s Cancer Center is committed to revealing the causes of cancer and translating basic scientific discoveries into improved ways to diagnose, treat and ultimately prevent cancer. You play a key role in facilitating the Burnham’s progress on this frontier through the San Diego Center for Chemical Genomics. What can you tell us about the next generation of cancer drugs?

A: The goal is to create drugs that by the specificity of their design and delivery, will be more effective in treating cancer and less toxic. The next generation of cancer drugs will be highly specific by inhibiting or promoting a defined molecule or pathway inside a cell. Tomorrow’s treatments for cancer might be a cocktail of several “drugs,” each acting on a different pathway involved in cancer.

We anticipate being able to create customized treatments, “personalized medicine,” that will be tailored to an individual patient based on what we know about that patient’s disease at the genomic and molecular level. Because the drugs will act on specific targets, side effects should be greatly reduced.

Q: Burnham has made several key contributions to understanding cancer during its 25-year partnership with the NCI as a Cancer Center. How will Burnham make an impact in the next few years?

A: We will continue to leverage our knowledge of the fundamentals of cancer biology to enhance drug discovery and translational research. Burnham’s Cancer Center, through its outstanding basic science, drug discovery effort and partnering with academic and private sector collaborators, is poised to make significant contributions by identifying new strategies for therapeutic intervention and by generating innovative prototype drugs.

Q: How will Burnham’s expansion into Florida enhance our cancer research efforts?

A: In Florida we will establish expertise that complements our research in La Jolla, particularly in the areas of chemistry and pharmacology. There will be at least two hospitals near Burnham in Orlando’s Lake Nona research and health care complex, which present the possibility of building clinical collaborations, and we will be able to build tissue banks from cancer patients to support our medical research.

Q: If you could accomplish one thing, what would it be?

A: Our mission is to move toward finding cures of diseases. Already we have examples where our discoveries were translated into treatments that benefit cancer patients, but we have not yet cured cancer. That’s the ultimate goal. www.burnham.org

5

Philanthropy

Matters Making a Difference

in the Race Against Disease

6

Last Saturday morning, while

racing team to build community

“I will be raising money to

most of us were still in our beds

awareness for the Institute and to

support Alzheimer’s disease

dreaming, members of Team

raise funds to accelerate the pace

research in memory of my

Burnham for Medical Research were stretching, socializing and gearing up for their 18-mile run/walk. In fact, every Saturday for the past four months, our dedicated Team Burnham members have exerted themselves in these early morning Saturday group runs/walks as they train for the upcoming Rock ‘n’ Roll Arizona Marathon and HalfMarathon on January 14, 2007 in Phoenix. The group runs are just one part of a grueling sixmonth training schedule for the team.

On August 1, 2006, the Burnham launched its first ever

of discovery in stem cell research,

grandmother who recently

cancer, Alzheimer’s disease,

passed away from the disease,”

arthritis, multiple sclerosis, ALS,

said Claire Hill, External

diabetes, and diseases of the

Relations Foundation and

brain and nervous system.

Corporate Giving Manager.

John C. Reed, M.D., Ph.D.,

While training for the race,

President and CEO of Burnham,

each member of Team Burnham

leads our team, comprised of

was asked to raise $3,000 to

many of the Institute’s scientific

support the innovative research

leadership, as well as friends of

efforts underway at the Institute.

the organization from San Diego,

As of December 12, team

Phoenix and across the country.

members raised $54,965 from

Although the team encompasses

approximately 460 donations.

a variety of experience

These funds were raised in

levels, training schedules and

a number of creative ways,

motivations, our team shares a

including direct appeals to friends

common interest in doing its part

and family, hosting small events

to conquer disease.

and approaching corporations

www.burnham.org

Burnham Remembers ERIC PRESTON DUDL October 22, 1972 – August 30, 2006

Team Burnham taking it to the streets.

and organizations both large and small to support their goal.

It’s not too late to support our team! For more information or to make a donation, please contact Team Manager Amber Evans at (858) 646-3103 or teamburnham@burnham.org.

Click here to learn more about Team Burnham.

Eric passed away peacefully in his father’s arms succumbing to a cancer that could not be stopped by all known medical treatments.

He was caring to the end, his last thoughts were unselfishly for his work, family and dear girlfriend, Lilia.

After earning his Ph.D. in biochemistry and immunology in 2005 from the University of Southern California, he had just started a postdoctoral fellowship at the Burnham pursuing his passion for cancer research. Eric published several research papers focused on cancer at the cellular level. It was his wish that he could contribute lasting research that would save lives. Cancer did not stop Eric from going to work every day when he was out of the hospital. His courage in the face of pain was a source of wonder for his family, friends, and co-workers. Eric set his goals and standards high and achieved them in spite of great difficulties.

Burnham was his big leap forward. He was so impressed with his mentor, Dr. John Reed, he could hardly contain himself. He said John would work with him as his guide, help him develop ideas and experiments, and make sure he

Eric left a lasting immpression on the researchers and staff at the Burnham.

had what he needed to succeed.

After he was hospitalized with a lung clot, a friend suggested he take disability. He said, “why would I do that, I have the perfect job. Why would anyone give that up?” Eric never missed a single day of work when he wasn’t hospitalized.

And because he felt so strongly that the Burnham was doing the right thing, he left as much money as he could to allow someone else to continue on with the work.

The Burnham has developed the Eric Dudl Scholarship Fund in his memory, an endowment fund whose interest will be available each year to be awarded by the President/CEO to a postdoctoral trainee to support educational endeavors.

Eric will be missed by family members, colleagues and friends.

Click here to learn more about Eric Dudl Scholarship Fund.

“When he told me in February that he had cancer I told him how scared I was for him and his family. He told me not to be scared. And when I told him he was crazy for coming to work instead of taking time to do all the things he wanted to do, he said that working in the lab, helping to find cures for cancer, was what he wanted to do.” —Mike Thomas “I was lucky enough to have known Eric through the Tony Robbins forum where he shared with us an unstoppable love of life, learning, and courage! Whilst we shed tears for having lost a friend, we rejoice in the knowledge that he knew whatever may be, may be, and that he was living life to the fullest!” —Tracey Farrell “You will stay in my thoughts a dear, unique, incredibly courageous, enthusiastic and humorous colleague, and co-worker. Your courage and determination in medical research and in your individual fight will stay in my mind as an incredible example to follow. I am glad to have the honor to know you.” —Gaelle Le Negrate

www.burnham.org

7

GALA 2006

& “Fire & Ice” was the Burnham’s best gala yet! Thanks to the talented efforts of Gala Chair Muffy Walker and Honorary Gala Chair Betsy Manchester, 450 guests celebrated the Institute’s 30th anniversary in grand style at... The Grand Del Mar, a luxury resort and golf club opening in fall 2007. The evening began with a reception in Addison, the resort’s signature restaurant, followed by dinner catered by the Manchester Grand Hyatt in a lavish tent set aglow with neon flames. World-class ice skaters, fire dancers and the former California Governor and first lady, Pete and Gayle Wilson, stole the show as they honored philanthropists Malin and Roberta Burnham. This year’s gala netted $850,000 for medical research, a 91% increase over last year’s annual fundraiser! We couldn’t have done it without the generous support of our title sponsors Papa Doug and Betsy Manchester and Invitrogen, along with a veritable “Who’s Who” of guests. The most successful auction item, “Fund a Need,” raised more than $300,000 to support Alzheimer’s research at the Burnham.

Click here to view additional pictures.

8

www.burnham.org

California’s former first lady, Gayle, and former California Governor, Pete Wilson

Julie Ames and Greg Lucier from Invitrogen with Bob Klein from California Institute of Regenerative Medicine

Malin and Roberta Burnham, Muffy Walker and John Reed, Burnham President and CEO, with Betsy and Papa Doug Manchester

Founder Lillian Fishman and daughter Nina Fishman

Gala Chair Muffy Walker

Honorary Gala Chair Betsy Manchester

Gary and Jeanne Herberger, Charlie and Judy Jones, Jean and Jack Hardy, with Ed and Jane Gillenwaters

Frank and Lee Goldberg with Toby and Howard Cohen

Nico Nierenberg, Burnham Chairman of the Board

Former California Governor and first lady, Pete and Gayle Wilson, with Audrey Geisel and Alex Butterfield

Burnham President and CEO John Reed

Al and Armi Williams with Jan and Lael Kovtun

www.burnham.org

9

STARS and the

Burnham Institute for Medical Research A successful partnership to end suffering caused by neurological diseases Science, Technology and Research Support, or STARS, a Los Angeles-based volunteer organization made up of individuals dedicated to providing a cure for those suffering from neurological diseases, has given the Burnham Institute for Medical Research $226,000 over a five-year period, including a gift of $55,000 received earlier this year.

“We are grateful for what the devoted individuals associated with STARS have done for the Burnham’s research efforts,” says Dr. John Reed, President and CEO. “Their remarkable generosity has allowed our researchers to make advances on a number of devastating diseases, such as ALS, Alzheimer’s and Parkinson’s; advances that would not have been possible without STARS’ support. We cannot thank the STARS membership enough for their dedication to our research and the people suffering from disease.”

10

www.burnham.org

In honor of the organization’s continued commitment to medical research, a lab in the Del E. Webb Center for Neuroscience and Aging Research at the Burnham has been dedicated in memory of Marlene Malouf Hall, a past president of the STARS organization. Mrs. Hall, who suffered from ALS, passed away a few years ago.

“I speak for all of our members when I tell you how proud we are to have been instrumental in successfully supporting the excellent medical research being done at the Burnham,” says Arlene Brownson, current President of STARS. The STARS annual fundraiser to support neuro­logical disease research was held Wednesday, November 29 at the beautiful Riviera Country Club in Pacific Palisades. The event, which was the organization’s largest and most successful yet, featured a luncheon, a silent auction, and a presentation from a

Burnham representative. One hundred percent of the event was underwritten by STARS members, making all of the proceeds available to aid in disease research.

Click here to learn more about making a donation.

Burnham Director of External Relations Chris Lee accepts the donation from STARS President Arlene Brownson at a luncheon in Los Angeles.

The Legacy

Society Profile of a Donor: Gwen Laidlaw Gwen Laidlaw has designated her gift annuities to fund state-of-the-art laboratory equipment.

Gwen Laidlaw is battling Leiomyo­sarcoma, a rare cancer of the muscle tissue, with the resolve of a woman half her age. Eightynine years young, she was picture of health until four year ago.

Prior to the diagnosis, Gwen had never been to a doctor or taken a prescription medicine. “I received my master’s degree in nutritional research from Columbia University and never encountered an illness I couldn’t treat myself.”

Times have changed for Gwen. Now, her day is all about chemotherapy, radiation treatments and the pursuit of clinical trials. Gwen is more convinced than ever that medical research needs to stay focused on the campaign against cancer, regardless of the type. “Insurance companies don’t cover some of the newer experimental treatments, especially for rare types of cancer. That doesn’t leave

me with too many treatment options,” says Gwen.

Gwen met the External Relations staff from the Burnham a few years ago at Ocean Hills Country Club. They were presenting an update on medical research to the local residents.

She was impressed with the scientific breakthroughs made at the Burnham. When she learned they were offering Charitable Gift Annuities (CGA) at a 10.6% rate of return, she began purchasing them.

“Charitable Gift Annuities have been an important part of my retirement income,” says Gwen.

“I live off of Social Security and dividends from my investments with Morgan Stanley. I cash in appreciated stocks for gift annuities every year. I get a tax write off and use the increased revenue from CGA’s to pay for in-home care or unreimbursed

medical expenses for cancer treatments.” Gwen has CGA’s with the Burnham, Linus Pauling Institute, Salvation Army and Columbia University.

Gwen has designated her gift annuities to fund state-of-theart laboratory equipment, which she read about in the Burnham Report’s Wish List. When asked how philanthropy has connected her to the community, she says, “My late husband, Norman, and I had a wonderful life together. I wasn’t a volunteer, we didn’t have children and philanthropy has been one way I feel my life has made a mark on society.”

If you would like to receive more information about charitable gift annuities, contact Patty Fuller at pfuller@burnham.org or (858) 795-5231.

Click here to learn more about Charitable Gift Annuities. www.burnham.org

11

Burnham

Wish List This issue, we are featuring equipment needs for our Medicinal Chemistry Facility, ADMET/PK, or

Autosampler.................................................... $10,000 Automation to allow analysis of many drug samples

Absorption, Distribution, Metbolism, Excretion, Toxicity

HPLC column.................................................... $1,600

and Pharmacokinetics. This state-of-the-art equipment will

To separate and recover drug candidates from mixtures

enable researchers to take “hits” from high through-put chemical compound screens, and determine whether they

HPLC pump....................................................... $5,800

have “drug-like” properties. These properties include lack

High pressure pump separates drug from byproducts or blood

of toxicity, being absorbed and distributed in the blood, and not being rapidly degraded or excreted. Such analysis is an important first step in moving from lead compounds

UV-Vis Detector................................................. $7,000 Accurately analyzes quantity of drug (dose) in samples

discovered in the Burnham’s San Diego Center for Chemical

Reaction Incubation Apparatus........................... $5,100

Genomics toward useful therapeutic drugs.

For drug candidate synthesis CHO-hERG Cell System..................................... $4,500

Many thanks to our generous donors who called

Cultured cell assay predicts drug cardiac toxicity

in to respond to the Wish List published in our previous

Microvolume Pipettors.......................................... $850

issue of The Burnham Report. The following in‑kind and

To accurately dispense tiny amounts of liquid

cash donations were greatly appreciated by our scientists: Pfizer: Tenney T2C Incubator, Temp Range 75c – 200c, $5,000.00; Hemke Kabnet Centrifuge, $3,000.00; Nuaire

Rotary Evaporator............................................. $3,000 Rapidly dries samples under vacuum without loss

Biological Safety Cabinet, $3,000.00 Click here for more information or to donate now.

Mrs. David Beckman: (4) microscopes including Nicon e80 with computer, Nicon Ts 100, Microstar 110 vertical flow with camera, and Wilde m 32 valued at $80,000.00 Mrs. Gwen Laidlaw: Proceeds from a $10,000 Charitable Gift Annuity (CGA) will be used to purchase one microscope camera for observing brain images and two computers, one for recording brain surgery recordings, and the other to be used as a micro plate reader.

12

www.burnham.org

Burnham in the

Photo by Tim Middleton

Community

Yuehai Ke, Mari Enoksson, Lillian Fishman, Amy Howes, Lutz Tautz, and Sergio Alonso (not pictured).

Lillian Fishman presents the

2006 Fishman Fund Awardees The Fishman Award Fund is dedicated to helping support the promising research of young postdoctoral fellows. The fund was established by Mary Bradley and Reena Horowitz in honor of Dr. William and Mrs. Lillian Fishman, co-founders of the Burnham Institute for Medical Research.

Support the Burnham at

Infusions of Tea

Infusions of Tea, a La Jolla tea shop, has created a special blend of tea especially for the Burnham that we have affectionately named “Lillian’s Treasure” in honor of co-founder Lillian Fishman. Shop owner Ron Eng developed our unique blend of organic green tea flavored with apple and pear, which is perfect hot or cold.

This partnership was inspired by the work of Burnham scientists Maurizio Pellecchia and John Reed, President and CEO, who identified anti-cancer agents in green and black teas.

Nearly 100 people joined us for the unveiling of Lillian’s Treasure at Infusions of Tea located at 8750 Genesee Ave, Suite 258 in La Shop owner Ron Eng discusses the health benefits of tea with his customers.

Jolla’s Costa Verde Shopping Center. As part of this partnership, Ron has generously agreed to donate 10 percent of sales from “Lillian’s Treasure” to support the Burnham’s research. For more information or a sample of this tea, contact Jocelyn Wyndham at the Burnham Institute at (858) 795-5216 or jwyndham@burnham.org.

Click here to learn about this discovery.

www.burnham.org

13

Calendar of Events January 14, 2007

March 2007 (Date TBD)

Team Burnham for Medical Research

President’s Council Event

Support team members as they prepare for the Phoenix Rock ‘n’ Roll Marathon & Half Marathon.

(See article in this issue of The Burnham Report)

Burnham Institute for Medical Research, Mainly Mozart and San Diego Museum of Art present,“Exploring the Late Phase of Creativity.”

For more information, please contact Jocelyn Wyndham at (858) 795-5216 or jwyndham@burnham.org.You can subscribe to The Burnham Report as a virtual magazine online by simply emailing externalrelations@burnham.org

Notes & News Stefan Riedl, Ph.D., was recently named as one of 15 cancer researchers to receive the prestigious 2006 V Foundation Scholar Grant. Dr. Riedl, recently appointed Assistant Professor at Burnham, will receive $100,000 over a two-year period to support his research project, “Exploring the structural mechanisms of cancer signaling complexes for drug development.”

Click here to learn more

Dr. Sara Courtneidge awarded honorary degree. The University of Leeds recently recognized Dr. Sara Courtneidge with the degree of Doctor of Science, honoris causa. Dr. Courtneidge, a Leeds alumnus, was honored for her 30 years of as a world leader in cancer research, established early on with her work on the oncogene Src, the first cancer-causing gene identified.

Dr. Courtneidge directs the Cell Adhesion and Extracellular Matrix Biology Program in the Cancer Center at Burnham.

Click here to learn more

Burnham Awarded $12.7 Million from National Institutes of Health to Support Neuroscience Collaboration among Burnham Institute for Medical Research, Salk Institute for Biological Studies, The Scripps Research Institute, and University of California, San Diego. The five-year grant will support neuroscience technologies in 13 core areas, including: stem cells, proteomics, crystallography and nuclear magnetic imaging work, structural biology, functional genomics, genetic analysis, neurological behaviors in mice, diseases of nerve cells, electrophysiology studies of nerve impulse transmission, drug screening, and biostatistics and computational modeling. Dr. Stuart Lipton directs this collaborative grant.

Click here to learn more

Nonprofit For more information onOrganization the U.S. Postage virtual magazine product click here.

PAID

The Burnham Institute 10901 North Torrey Pines Road La Jolla, CA 92037 (858) 646-3100 www.burnham.org

www.virtualmarketingpartners.com